Compare BY & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BY | HROW |
|---|---|---|
| Founded | 1914 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2017 | N/A |
| Metric | BY | HROW |
|---|---|---|
| Price | $29.21 | $45.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $33.67 | ★ $68.86 |
| AVG Volume (30 Days) | 197.2K | ★ 712.5K |
| Earning Date | 01-22-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | ★ 1.54 | N/A |
| EPS | ★ 2.80 | N/A |
| Revenue | ★ $400,663,000.00 | $250,042,000.00 |
| Revenue This Year | $19.26 | $39.05 |
| Revenue Next Year | $3.88 | $40.48 |
| P/E Ratio | $10.42 | ★ N/A |
| Revenue Growth | 7.23 | ★ 47.83 |
| 52 Week Low | $22.63 | $20.85 |
| 52 Week High | $32.05 | $50.72 |
| Indicator | BY | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 65.80 | 65.36 |
| Support Level | $27.82 | $39.64 |
| Resistance Level | $28.45 | $42.44 |
| Average True Range (ATR) | 0.55 | 2.33 |
| MACD | 0.21 | 0.85 |
| Stochastic Oscillator | 90.54 | 80.37 |
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.